Tenet Healthcare price target raised to $130 from $120 at Truist

Truist analyst David MacDonald raised the firm’s price target on Tenet Healthcare to $130 from $120 and keeps a Buy rating on the shares. The firm remains positive on the stock following the company’s strong Q1 results, with both revenue and adjusted EBITDA well ahead on solid hospital volumes, brisk revenue per case growth, and robust cost management, the analyst tells investors in a research note.